Kadimastem plans to submit an amendment to the protocol of its ongoing Phase 1/2a trial in Israel assessing the use of AstroRx, an off-the-shelf stem cell therapy, for the treatment of amyotrophic lateral sclerosis (ALS).
The company wants to change the planned dosage in one of the studys cohorts and test repeated injections of a low dose of AstroRx, instead of the medium dose that was originally planned.
The request is based on positive interim data from the first set of five patients given a single intrathecal (into the spinal canal) injection of the lowest dose (100 x 106 cells) of AstroRx. At this dose, the therapy was found to be safe with no serious side effects or dose-limiting toxicities identified, according to the data, which was released in September.
Moreover, AstroRx significantly reduced disease progression after three months of treatment, compared to the start (baseline) of the trial. The ALS Functional Rating Scale revised (ALSFRS-R) score decreased on average by 0.87 per month during the three months before treatment; however, it started to increase again (on average by 0.26 per month) in the three months after treatment. The ALSFRS-R score is a validated assessment of disability progression, with lower scores indicating greater motor impairment.
Evidence suggests that poorly working astrocytes (cells which support and protect neurons) are involved in the progression of ALS. AstroRx is composed of healthy functional astrocytes, which have been derived from human embryonic stem cells. The treatment, injected into a patients spinal fluid, is thought to compensate for the diseased astrocytes and prevent the death of motor neurons, thereby slowing disease progression.
AstroRx was granted orphan drug status by the U.S. Food and Drug Administration in November 2018 for the treatment of ALS.
Preclinical (in the lab) studies have shown that AstroRx was safe, delayed disease onset, maintained muscle function, and increased survival in rodent models of ALS.
The ongoing open-label Phase 1/2a clinical trial (NCT03482050) is testing the safety and effectiveness of AstroRx in ALS patients. The trial is being conducted at Hadassah Ein-Kerem Medical Center in Israel where it recruited 21 patients withearly stagedisease.
The trials original protocol included four doses of AstroRx delivered into the spinal canal: a low (100 x 106 cells), medium (250 x 106 cells), or high (500 x 106 cells) dose.
The primary outcome of the trial is to assess the safety and tolerability of AstroRx. Secondary outcome measures include changes in patients ALSFRS-R scores, respiratory muscle strength, hand grip strength, limb muscle strength, and quality of life.
In cohort A, participants received a single low dose of the therapy. In cohort B, participants received a single medium dose of the therapy. Results from cohort A are expected to be reported by the end of 2019, and cohort B results are expected in 2020.
Based on the positive interim results from cohort A, Kadimastem is seeking to amend the therapy regime being assessed in cohort C and D, so that cohort C will receive two injections of the low dose (instead of the originally planned medium dose), with the injections being separated by two to three months. Results from this section of the trial are expected to be reported in the first half of 2021. Under the amendment, cohort D participants will receive the regimen originally planned for cohort C (repeated administration of the medium dose, 250 x 106). Cohort D dosing will be dependent on the results of the previous cohorts.
We are the first to treat ALS patients with astrocyte cells. Following our positive interim results, we look forward to achieving a prolonged therapeutic effect in the repeated low dose administration, bringing new hope for patients with this incurable disease Rami Epstein, CEO of Kadimastem, said in a press release.
Kadimastem expects to submit an investigational new drug application to the U.S. Food and Drug Administration by mid-2021 with the aim of testing AstroRx in a multi-center clinical trial, which will compare the current and frozen version of the therapy.
Patricia holds a Ph.D. in Cell Biology from University Nova de Lisboa, and has served as an author on several research projects and fellowships, as well as major grant applications for European Agencies. She has also served as a PhD student research assistant at the Department of Microbiology & Immunology, Columbia University, New York.
Total Posts: 279
Margarida graduated with a BS in Health Sciences from the University of Lisbon and a MSc in Biotechnology from Instituto Superior Tcnico (IST-UL). She worked as a molecular biologist research associate at a Cambridge UK-based biotech company that discovers and develops therapeutic, fully human monoclonal antibodies.
View post:
ALS Stem Cell Therapy Developer Seeks Amendment to its AstroRx Trial - ALS News Today
- Jake Diekman throws BP session for Rangers | MLB.com - MLB.com - August 6th, 2017 [August 6th, 2017]
- Cerebral palsy: Symptoms, diagnosis, treatment - December 5th, 2017 [December 5th, 2017]
- Hypothalamus - the body's thermostat | ASU - Ask A Biologist - December 6th, 2017 [December 6th, 2017]
- When Stroke Affects the Thalamus - Stroke Connection ... - December 28th, 2017 [December 28th, 2017]
- The Endocrine System: Hypothalamus and Pituitary - December 28th, 2017 [December 28th, 2017]
- Hypothalamus - Anatomy, Blood supply and Function | Kenhub - December 28th, 2017 [December 28th, 2017]
- Ulcerative Colitis - Cedars-Sinai - January 6th, 2018 [January 6th, 2018]
- Ulcerative colitis - Treatment - NHS.UK - January 7th, 2018 [January 7th, 2018]
- Business Directory | Uptown Waterloo Business Improvement Area - January 8th, 2018 [January 8th, 2018]
- Will States Continue To Fund Stem Cell Research? : Shots ... - January 28th, 2018 [January 28th, 2018]
- Spinal Cord Injuries - emedicine.medscape.com - February 15th, 2018 [February 15th, 2018]
- Spinal Cord Injuries - spine.org - February 15th, 2018 [February 15th, 2018]
- Journal of Clinical & Experimental Cardiology - Open Access Journals - April 10th, 2018 [April 10th, 2018]
- Cardiology Treatment - Fortis Healthcare - April 10th, 2018 [April 10th, 2018]
- Biology Junction - April 12th, 2018 [April 12th, 2018]
- Managing Right Ventricular Failure in PAH: An Algorithmic ... - April 14th, 2018 [April 14th, 2018]
- Ticagrelor vs Clopidogrel After Fibrinolytic Therapy in ... - April 22nd, 2018 [April 22nd, 2018]
- Cardiovascular Pharmacotherapeutics: William H. Frishman ... - May 13th, 2018 [May 13th, 2018]
- 13 Super Foods Good for Eczema - Top Eczema Treatments - May 15th, 2018 [May 15th, 2018]
- Diagnosis & Treatment of Parkinson's - ParkinsonsDisease.net - May 30th, 2018 [May 30th, 2018]
- Arizona Heart Rhythm Center - June 10th, 2018 [June 10th, 2018]
- Ayurvedic Medicines for Ulcerative Colitis | Natural ... - June 21st, 2018 [June 21st, 2018]
- Weinstein Cardiovascular Development and Regeneration Meeting - June 30th, 2018 [June 30th, 2018]
- Ulcerative Colitis Information Centre - July 31st, 2018 [July 31st, 2018]
- Sudden Death in Dogs - Pet Health Network | Pet Health ... - August 7th, 2018 [August 7th, 2018]
- Coronary Heart Disease - Ischaemic heart disease - British ... - August 21st, 2018 [August 21st, 2018]
- Cardiac Rehabilitation: Overview, History and Definition ... - August 25th, 2018 [August 25th, 2018]
- Difference between Cardiac Arrest and Respiratory Arrest ... - August 25th, 2018 [August 25th, 2018]
- ECM for Pericardial Closure - Aziyo - August 25th, 2018 [August 25th, 2018]
- Adult Mental Health | Georgia Department of Behavioral Health ... - September 6th, 2018 [September 6th, 2018]
- Mental Health | ECLKC - September 6th, 2018 [September 6th, 2018]
- Mental Health - The Church of Jesus Christ of Latter-day Saints - September 6th, 2018 [September 6th, 2018]
- Center for Vascular Biology - Home | UConn Health - September 22nd, 2018 [September 22nd, 2018]
- # Diabetes Stem Cell Research Diabetes Care Measures - September 30th, 2018 [September 30th, 2018]
- Cardiac Rhythm Disturbances | The Patient Guide to Heart ... - November 2nd, 2018 [November 2nd, 2018]
- Arrhythmia | Cleveland Clinic - November 2nd, 2018 [November 2nd, 2018]
- Hyperbaric Oxygen Therapy for Wound Healing | Johns ... - November 13th, 2018 [November 13th, 2018]
- NIMH Home - November 24th, 2018 [November 24th, 2018]
- What is an interventional cardiologist? | Heart Surgeries ... - November 26th, 2018 [November 26th, 2018]
- Molecular Cardiology Research Institute Boston | Tufts ... - November 29th, 2018 [November 29th, 2018]
- Lower vascular plant | botany | Britannica.com - December 7th, 2018 [December 7th, 2018]
- Welcome to the ABG Tutorial Welcome to Hansen - December 12th, 2018 [December 12th, 2018]
- Cardiac catheterization - Wikipedia - December 12th, 2018 [December 12th, 2018]
- Stem Cell Research & Therapy | Home page - December 22nd, 2018 [December 22nd, 2018]
- Journal of Stem Cell Research and Therapy- Open Access ... - December 22nd, 2018 [December 22nd, 2018]
- Stem-cell therapy - Wikipedia - December 22nd, 2018 [December 22nd, 2018]
- Cardiology and Interventional Cardiology - December 23rd, 2018 [December 23rd, 2018]
- Rhode Island Interventional Cardiology | Cardiovascular ... - December 23rd, 2018 [December 23rd, 2018]
- Interventional Cardiology Certification Policies | ABIM.org - December 23rd, 2018 [December 23rd, 2018]
- Interventional Cardiology - Boston Scientific - December 23rd, 2018 [December 23rd, 2018]
- 9 Benefits of Human Growth Hormone (Along with Side ... - December 27th, 2018 [December 27th, 2018]
- Growth hormone deficiency - Wikipedia - December 27th, 2018 [December 27th, 2018]
- Dr. Lorrie Kirshenbaum, Cardiac Gene Biology | St ... - January 28th, 2019 [January 28th, 2019]
- Cardiomyopathy - CardioSmart - February 8th, 2019 [February 8th, 2019]
- Centenary Institute | Medical Research, Life Saving Research - February 24th, 2019 [February 24th, 2019]
- Cardiovascular Medicine | Department of Medicine - March 29th, 2019 [March 29th, 2019]
- Rapid Test Market 2019 with Recent Trends, Revenue, Demand and Top Manufactures- Bureau Veritas, SGS SA, Intertek Group plc, Eurofins Scientific -... - October 11th, 2019 [October 11th, 2019]
- Medical Imaging Equipment Market Research Report 2019: Global Industry Analysis, Business Development, Size, Share, Trends, Future Growth, Forecast To... - October 11th, 2019 [October 11th, 2019]
- Analysis on the Global DNA Read, Write & Edit Market, 2017-2019 and Forecast to 2024 - Yahoo Finance - October 11th, 2019 [October 11th, 2019]
- Cardiac Surgery Instruments Market is Expected to Tread a Steady Growth Trajectory by Clocking a CAGR of 5.9% from 2017 to 2022 - Health News Office - October 24th, 2019 [October 24th, 2019]
- PEDIATRIC MEDICAL DEVICES MARKET IS PROJECTED TO EXPAND AT A CAGR OF 8.0% FROM 2018 TO 2026 - Health News Office - November 1st, 2019 [November 1st, 2019]
- myTAIHEART Test Provides Evidence for Injury from Biopsy of Heart Transplant Recipients Cardiology2.0 - Cardiology2.0 - November 1st, 2019 [November 1st, 2019]
- Mental health and your heart - British Heart Foundation - November 19th, 2019 [November 19th, 2019]
- BUZZ-U.S. STOCKS ON THE MOVE-Cango, Gulfport Energy, Abiomed, Standard Diversified, Wanda Sports, Eidos - Nasdaq - November 19th, 2019 [November 19th, 2019]
- Cost Analysis of COPD Exacerbations and Cardiovascular Events in SUMMIT - AJMC.com Managed Markets Network - November 19th, 2019 [November 19th, 2019]
- Hundreds walk to defeat ALS in Ancient City - St. Augustine Record - November 22nd, 2019 [November 22nd, 2019]
- Living with Lung Cancer: The Silver Linings - Curetoday.com - November 22nd, 2019 [November 22nd, 2019]
- Building the human spinal cord atlas - SynBioBeta - November 22nd, 2019 [November 22nd, 2019]
- The Week That Wasn't: Keto and the Flu, Human Cyborg, Duvet Disease - Medscape - November 22nd, 2019 [November 22nd, 2019]
- ALS advance offers hope for those diagnosed with deadly disease - WRAL.com - November 22nd, 2019 [November 22nd, 2019]
- Former Boston Globe writer, current NHL executive Snow diagnosed with ALS | College Hockey - USCHO - December 23rd, 2019 [December 23rd, 2019]
- AB Science announces the publication of new results in the peer-reviewed journal Glia that further support masitinib's potential mode of action in ALS... - December 23rd, 2019 [December 23rd, 2019]
- Christmas in the City thrills homeless families, takes on poignancy with founders ALS diagnosis - The Boston Globe - December 23rd, 2019 [December 23rd, 2019]
- Amylyx Pharmaceuticals Announces AMX0035 Demonstrated Statistically Significant Treatment Benefit for People with ALS in the CENTAUR Trial - Business... - December 23rd, 2019 [December 23rd, 2019]
- RADICAVA (edaravone) - December 23rd, 2019 [December 23rd, 2019]
- List of Amyotrophic Lateral Sclerosis Medications (5 Compared ... - December 23rd, 2019 [December 23rd, 2019]
- Neuropore Completes Phase 1 Clinical Trial in Healthy Volunteers with NPT520-34, a Therapeutic Candidate Aimed at Treating Parkinson's Disease and... - January 14th, 2020 [January 14th, 2020]
- Comprehensive Analysis on Prostacyclin Market based on types and application - Technology Magazine - January 18th, 2020 [January 18th, 2020]
- N.J. karate legend who inspired thousands loses battle with ALS - NJ.com - January 18th, 2020 [January 18th, 2020]
- Denali Therapeutics Announces Broad Pipeline Progress Including Positive Results From Its LRRK2 Program for Parkinson's Disease - Associated Press - January 18th, 2020 [January 18th, 2020]